SCHEMBL1005880

SCHEMBL1005880

COc1cc(C#Cc2ccc(O)cc2)cc(OC)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.77
ABL1 P00519 5/20 0.59
ABCB1 P08183 5/20 0.59
BCR P11274 5/20 0.59
TTR P02766 2/20 0.53
CYP1A1 P04798 2/20 0.53
ALOX5 P09917 2/20 0.53
PTGS2 P35354 2/20 0.53
CYP1B1 Q16678 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
NQO2 P16083 1/20 0.53
PTGS1 P23219 1/20 0.53
MAPK1 P28482 1/20 0.53
RAB9A P51151 1/20 0.53
GFER P55789 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15014186 0.87 APP (1.00) APPGAALTA4HESR2PDE4D
SCHEMBL15014229 0.87 APP (1.00) APPGAALTA4HESR2PDE4D
SCHEMBL673820 0.87 APP (0.69) APPABL1ABCB1BCRTTR
SCHEMBL29624580 0.85 ABL1 (0.59) APPABL1ABCB1BCRTTR
SCHEMBL21836129 0.85 ABL1 (0.59) APPABL1ABCB1BCRTTR
SCHEMBL674040 0.84 ALDH1A1 (0.65) APPABL1ABCB1BCRTTR
SCHEMBL4528239 0.83 APP (0.59) APPMEN1GAAMAPTKMT2A
SCHEMBL15014175 0.82 APP (0.88) APPABL1ABCB1BCRKDM4E
SCHEMBL712263 0.82 APP (0.52) APPABL1ABCB1BCRCYP1A1
SCHEMBL4421116 0.82 APP (0.81) APPCYP1A1PTGS2CYP1B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 US disclosed
US-20220296538-A1 Substituted Tolans for the Modulation of Microbial Colonization BioMendics, LLC (US) 2022-09-22 US disclosed
US-11351126-B2 Substituted tolans for the modulation of microbial colonization BioMendics, LLC (US) 2022-06-07 US disclosed
US-20210228501-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2021-07-29 US disclosed
US-20200206154-A1 Substituted Tolans for the Modulation of Microbial Colonization BioMendics, LLC (US) 2020-07-02 US disclosed
US-10426742-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2019-10-01 US disclosed
US-20190022029-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2019-01-24 US disclosed
US-20160296477-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2016-10-13 US disclosed
US-20130131390-A1 PROCESS FOR THE PRODUCTION OF SUBSTITUTED ELECTRON RICH DIPHENYLACETYLENES DSM IP ASSETS B.V. (NL) 2013-05-23 US disclosed
EP-2456742-A2 PROCESS FOR THE PRODUCTION OF SUBSTITUTED ELECTRON RICH DIPHENYLACETYLENES DSM IP Assets B.V. (NL) 2012-05-30 EP disclosed
WO-2011009888-A2 PROCESS FOR THE PRODUCTION OF SUBSTITUTED ELECTRON RICH DIPHENYLACETYLENES DSM IP ASSETS B.V. (NL) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB APP 4010/4885ABL1 2543/4885ABCB1 2309/4885
US-20200206154-A1 Substituted Tolans for the Modulation of Microbial Colonization LMAN1, DPM1, DSTN APP 3466/4885ABL1 1044/4885ABCB1 2217/4885
US-20160296477-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB APP 4260/4885ABL1 2939/4885ABCB1 2452/4885
US-20210228501-A1 Formulation and Process for Modulating Wound Healing ATG7, SQSTM1, ATF4 APP 3850/4885ABL1 2536/4885ABCB1 1776/4885
US-10426742-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB APP 4010/4885ABL1 2543/4885ABCB1 2309/4885
US-20190022029-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB APP 4010/4885ABL1 2543/4885ABCB1 2309/4885
US-11351126-B2 Substituted tolans for the modulation of microbial colonization LMAN1, DPM1, DSTN APP 3466/4885ABL1 1044/4885ABCB1 2217/4885
US-20220296538-A1 Substituted Tolans for the Modulation of Microbial Colonization LMAN1, DPM1, DSTN APP 3466/4885ABL1 1044/4885ABCB1 2217/4885
US-20130131390-A1 PROCESS FOR THE PRODUCTION OF SUBSTITUTED ELECTRON RICH DIPHENYLACETYLENES ETFB, TBCB, ETFA APP 2534/4885ABL1 815/4885ABCB1 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.